https://www.prognyx.com/blog/spectrum-terminates-its-648-patient-poziotinib-exon-20-phase-2-a-business-call-nPrognyxen2026-06-15Spectrum Exits the Poziotinib Exon 20 Program: Four Trials Halted, Stated Reasons Explicitly Exclude Safety